


**Product Name** : Samuraciclib  
**Cat. No.** : PC-61916  
**CAS No.** : 1805833-75-3  
**Molecular Formula** : C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O  
**Molecular Weight** : 394.523  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



2. Patel H, et al. **Mol Cancer Ther.** 2018 Mar 15.  
 pii: molcanther.0847.2016.

## Biological Activity

ICEC0942 (Samuraciclib, CT7001) is a potent, selective, orally active **CDK7** inhibitor with IC<sub>50</sub> of 41 nM, displays 15-fold selectivity over CDK2 (IC<sub>50</sub>=578 nM).

ICEC0942 displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2, CDK5 and CDK9.

ICEC0942 demonstrates sensitivity against a wide range of cancer types with GI<sub>50</sub> values ranging between 0.2-0.3 μM.

ICEC0942 shows substantial anti-tumor effects in xenografts of both breast and colorectal cancers, also exhibits complete growth arrest of ER-positive tumor xenografts combined with tamoxifen.

## References

Hazel P, et al. **ChemMedChem.** 2017 Mar 7;12(5):372-380.

